Impact of Pretreatment Emotional Distress on Survival and the Predictive Role of Peripheral Biomarkers in Immunotherapy Response Among Gastroesophageal and Lung Cancer Patients

Cohort 1 \& 2 Inclusion Criteria: * Meet the diagnostic criteria for cancer (including esophageal, gastric, GEJ or NSCLC) through clinical, pathological, and imaging examinations; * Karnofsky Performance Status (KPS) score should be equal to or greater than 80 points; * Unresectable locally advanced or metastatic; * Systematic treatments naive ( e. g., chemotherapy, anti-angiogenic drugs, targeted drugs, and immunotherapy); * Presence of at least one measurable lesion according to the Response Evaluation Criteria in Advanced Solid Tumors version 1.1 (RECIST v1.1); * Receiving PD-1/PD-L1 inhibitors monotherapy or combination with chemotherapy; * Informed and agreed to participate in the study; * Required to complete the questionnaire independently or with assistance from others if needed; * Legal age, 18 years or older. Exclusion Criteria: * Oncogene-driver positive; * Combined with other malignant tumors in the past 3 years; * Concurrent acute or chronic psychiatric disorders; * Current receiving anti-depressive or anti-anxiety therapy or other psychotropic drugs; * Previous treatment with other clinical drug trials; * Patients with symptomatic brain metastasis; * Severe intellectual disabilities or other communication difficulties that hindered normal interaction.